keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine

keyword
https://www.readbyqxmd.com/read/28432646/is-there-a-role-for-ivabradine-in-the-contemporary-management-of-patients-with-chronic-heart-failure-in-academic-and-community-heart-failure-clinics-in-canada
#1
Sherryn Roth, Carlos Fernando, Sadia Azeem, Gordon W Moe
INTRODUCTION: In patients with heart failure (HF) and reduced ejection fraction, increased heart rate (HR) is an independent risk factor for adverse outcomes. In systolic HF treatment with the If inhibitor ivabradine trial (SHIFT), Ivabradine improved survival when added to conventional treatment including β-blockers. However, the extent of benefit in the real world is unclear. We examined the characteristics of patients on guideline-directed therapy and determined who had SHIFT-like characteristics...
April 21, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28431002/inappropriate-sinus-tachycardia-in-a-heart-transplant-successfully-treated-with-ivabradine
#2
Nishaki Mehta, Aneesh Bapat, Usha Tedrow, William Gregory Stevenson, Bruce Koplan
No abstract text is available yet for this article.
April 18, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/28423233/ivabradine-versus-metoprolol-in-patients-with-acute-inferior-wall-myocardial-infarction-expanding-arena-for-ivabradine
#3
Rajendra K Go Khroo, K Priti, Bhanwar L Ranwa, Kamal Kishor, Devendra Bisht, Sajal Gupta
BACKGROUND: Atrioventricular (AV) blocks are of concern with the use of beta blockers in inferior wall myocardial infarction (MI). Ivabradine lowers heart rate with a lesser risk of AV blocks. OBJECTIVES: To compare ivabradine with metoprolol in acute inferior wall MI in terms of feasibility, tolerability and efficacy METHODS: It was a prospective double blind single centre randomized controlled study. Of 1032 patients with acute inferior wall MI, 468 eligible patients were randomized in 1:1 manner to ivabradine (group A) and metoprolol (group B)...
April 19, 2017: Cardiovascular Therapeutics
https://www.readbyqxmd.com/read/28408104/long-term-treatment-with-ivabradine-over-12months-in-patients-with-chronic-heart-failure-in-clinical-practice-effect-on-symptoms-quality-of-life-and-hospitalizations
#4
C Zugck, S Störk, G Stöckl
BACKGROUND: Ivabradine is indicated to control heart rate in otherwise optimally treated patients with chronic heart failure (CHF) and reduced ejection fraction. However, data on its effectiveness outside clinical trials and longer-term effects are scarce. METHODS: We performed a prospective cohort study involving 249 German resident cardiologists and analyzed the 1-year effectiveness and safety of ivabradine used in CHF outpatients. Data on symptoms, quality of life, and hospitalizations were collected...
April 10, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28394465/integrating-new-pharmacologic-agents-into-heart-failure-care-role-of-heart-failure-practice-guidelines-in-meeting-this-challenge
#5
Kirkwood F Adams, Erika M Giblin, Natalie Pearce, J Herbert Patterson
Heart failure is well recognized as a major public health concern not only due to severe and frequent adverse health outcomes but also related to the major financial burden this syndrome presents with advancing age in Western societies. Despite the dire need for more efficacious therapies and better application of existing advances, treatment gaps persist, and outcomes in heart failure remain poor, with continually high mortality and morbidity. Treatment guidelines provide one strategy for advancing quality of care in patients with heart failure...
April 10, 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28375036/new-developments-in-the-pharmacotherapeutic-management-of-heart-failure-in-elderly-patients-concerns-and-considerations
#6
Elles M Screever, Wouter C Meijers, Dirk J van Veldhuisen, Rudolf A de Boer
Heart failure (HF) remains a major public health problem worldwide, affecting approximately 23 million patients, and is predominantly a disease of the elderly population. Elderly patients mostly suffer from HF with preserved ejection fraction (HFpEF), which often presents with multiple co-morbidities and they require multiple medical treatments. This, together with the heterogeneous phenotype of HFpEF, makes it a difficult syndrome to diagnose and treat. Areas covered: Although HF is most abundant in the elderly, this group is still underrepresented in clinical trials, which results in the lack of evidence-based medical regimens...
April 17, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28373625/modification-of-multiple-ion-channel-functions-in-vivo-by-pharmacological-inhibition-observation-by-threshold-tracking-and-modeling
#7
Chimeglkham Banzrai, Hiroyuki Nodera, Ryo Okada, Saki Higashi, Yusuke Osaki, Ryuji Kaji
Maintenance of axonal excitability relies on complex balance by multiple ion currents, but its evaluation is limited by in vitro single channel neurophysiological study on overall behavior. We sought to evaluate behaviors of multiple ion currents by pharmacological blockade. The threshold tracking technique was used to measure multiple excitability indices on tail sensory nerve of normal male mice before and after administration of either BaCl2 or ivabradine. Mathematical modeling was used to identify the interval changes of the channel parameters...
2017: Journal of Medical Investigation: JMI
https://www.readbyqxmd.com/read/28371247/ivabradine-current-and-future-treatment-of-heart-failure
#8
Lene Thorup, Ulf Simonsen, Daniela Grimm, Elise Røge Hedegaard
In heart failure (HF), the heart cannot pump blood efficiently and is therefore unable to meet the body's demands of oxygen, and/or there is increased end diastolic pressure. Current treatments for heart failure with reduced ejection fraction (HFrEF) include angiotensin-converting enzyme (ACE)-inhibitors, angiotension receptor type 1 (AT1 ) antagonists, β-adrenoceptor-antagonists, aldosterone receptor antagonists, diuretics, digoxin and a combination drug with AT1 receptor antagonist and neprilysin inhibitor...
April 2, 2017: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28363707/effects-of-ivabradine-on-heart-rate-and-hemodynamic-parameters-in-a-swine-model-of-cardiogenic-shock
#9
Marina Pascual Izco, Borja Castejón, María José Piedras, José Luis Zamorano, Marcelo Sanmartín, Carlos Zaragoza
No abstract text is available yet for this article.
March 28, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28361599/antianginal-therapy-for-stable-ischemic-heart-disease
#10
Santosh K Padala, Michael P Lavelle, Mandeep S Sidhu, Katherine P Cabral, Doralisa Morrone, William E Boden, Peter P Toth
Chronic angina pectoris is associated with considerable morbidity and mortality, especially if treated suboptimally. For many patients, aggressive pharmacologic intervention is necessary in order to alleviate anginal symptoms. The optimal treatment of stable ischemic heart disease (SIHD) should be the prevention of angina and ischemia, with the goal of maximizing both quality and quantity of life. In addition to effective risk factor modification with lifestyle changes, intensive pharmacologic secondary prevention is the therapeutic cornerstone in managing patients with SIHD...
January 1, 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28352365/heart-failure-modulates-electropharmacological-characteristics-of-sinoatrial-nodes
#11
Shih-Lin Chang, Hui-Lun Chuang, Yao-Chang Chen, Yu-Hsun Kao, Yung-Kuo Lin, Yung-Hsin Yeh, Shih-Ann Chen, Yi-Jen Chen
The impact of heart failure (HF) on sinoatrial node (SAN) channel regulation and electropharmacological responses has remained elusive. The present study aimed to investigate the effects of HF on the electrical activity of SANs with and without pharmacological interventions. Action potentials (APs) were recorded in isolated SANs from normal rabbits (control) and those with HF (rapid ventricular pacing for 4 weeks) prior to and after administration of a funny current blocker (ivabradine; 0.1, 0.3, 3 or 10 µM), a calmodulin kinase II inhibitor (KN-93; 0...
February 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28316174/-efficacy-and-safety-analysis-of-ivabradine-hydrochloride-treatment-of-chinese-patients-with-chronic-heart-failure-subgroup-analysis-of-chinese-patients-in-the-shift-study
#12
D Y Hu, D J Huang, Z Y Yuan, R P Zhao, X W Yan, M H Wang
Objective: To evaluate the efficacy and safety of ivabradine for the treatment of Chinese patients with chronic heart failure based on the Chinese subgroup data of the systolic heart failure treatment with the I(f) inhibitor ivabradine trial (SHIFT). Method: A total of 6 558 stable outpatients who presented symptoms of heart failure, with a left ventricular ejection fraction (LVEF) ≤35%, sinus rhythms with a heart rate ≥70 bpm participated in the randomized, double-blind, placebo-controlled, international multicenter clinical study...
March 24, 2017: Zhonghua Xin Xue Guan Bing za Zhi
https://www.readbyqxmd.com/read/28294866/-treatment-of-patients-with-stable-ischemic-heart-disease-in-real-clinical-practice-in-russia-the-choice-2-program
#13
G Glezer M, On Behalf Of The Choice-Study Participants On Behalf Of The Choice-Study Participants
OBJECTIVE: in the framework of an open post-marketing observational national program CHOICE-2 to assess correspondence between recommendations for management of patients with stable angina and actual clinical practice, as well as to assess effect of treatment with cytoprotector trimetazidine on clinical course of the disease. MATERIAL AND METHODS: Participating physicians (n=185 from 46 regions of Russian Federation) recruited 896 patients with ischemic heart disease (IHD)...
May 2016: Kardiologiia
https://www.readbyqxmd.com/read/28294865/-coronary-heart-disease-at-the-patient-with-metabolic-syndrome-strategy-of-antianginal-therapy
#14
N G Poteshkina, A A Troshina
Fist-line drugs in ischemic heart disease are -adrenoblockers. However there are cases when comorbidities limit possibilities of their use. In metabolic syndrome some representatives of this class unfavorably affect insulin sensitivity, carbohydrate and lipid metabolism. Alternative is to use ivabradine - selective inhibitor of If receptors with negative chronotropic activity. Ivabradine is metabolically neutral, has no negative inotropic effect, no influence on atrioventricular conduction and arterial pressure...
April 2016: Kardiologiia
https://www.readbyqxmd.com/read/28290845/-assessment-of-efficiency-of-medicamentous-therapy-in-correction-of-structurally-functional-changes-of-the-cardiac-muscle-at-patients-with-arterial-hypertension-in-combination-with-bronchial-asthma
#15
E I Tarlovskaya, A A Odegova
BACKGROUND: Bronchial asthma (BA) is a serious problem. It was found that the frequency of arterial hypertension (AH) detection in patients with asthma is about 30 %. At patients practically all types of violations of a warm rhythm meet a bronkhoobstruktivny syndrome. Emergence of rather new preparations - If-blockers, opens new opportunities in correction of heart rate (HR) and a cardioprotection at a combination of AH and BA. AIM: To assess therapy diltiazem-retard and ivabradine on structurally functional changes of a cardiac muscle and HR at patients with AH in combination with BA...
June 2016: Kardiologiia
https://www.readbyqxmd.com/read/28290829/-five-year-dynamics-of-main-clinical-symptoms-in-patients-with-ischemic-heart-disease-in-russia-in-comparison-with-other-countries-the-clarify-registry
#16
S A Shalnova, R G Oganov On Behalf Of The Participants Registry Clarify
The CLARIFY register (The prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) combined data of outpatients with stable coronary artery disease (CAD) from 45 countries including Russia. Purpose of this publication was to analyze dynamics of stable angina during 5 years of follow up in the Russian CLARIFY cohort compared with cohorts of patients from European and non-European countries. MATERIAL AND METHODS: Number of patients recruited in Russia was 2249...
January 2017: Kardiologiia
https://www.readbyqxmd.com/read/28290813/-causes-of-angina-pectoris-in-survivors-of-myocardial-infarction-and-the-role-of-optimization-of-antianginal-therapy-data-of-the-linkor-study-e
#17
M G Glezer, E I Astashkin On Behalf Of The Linkor Study Investigators
AIM: to analyze causes of attacks of angina pectoris and assess impact of optimization of antianginal therapy on frequency of attacks provoked by various factors. MATERIAL AND METHOD: We analyzed diaries of 1226 survivors of myocardial infarction (MI) which occurred within 12months before inclusion in the LINKOR program. Causes of pain and their changes with correction of antianginal therapy were registered during 16 weeks of follow-up. RESULTS: Participants of the study indicated the following factors as causes of pain: physical exertion (74...
December 2016: Kardiologiia
https://www.readbyqxmd.com/read/28289533/ivabradine-in-the-treatment-of-systolic-heart-failure-a-systematic-review-and-meta-analysis
#18
Mahesh Anantha Narayanan, Yogesh N V Reddy, Janani Baskaran, Abhishek Deshmukh, David G Benditt, Ganesh Raveendran
AIM: To perform a systematic-review and meta-analysis to compare outcomes of ivabradine combined with beta-blocker to beta-blocker alone in heart failure with reduced ejection fraction (HFrEF). METHODS: We searched PubMed, Cochrane, EMBASE, CINAHL and Web of Science for trials comparing ivabradine + beta-blocker to beta-blocker alone in HFrEF. We performed a systematic-review and meta-analysis of published literature. Primary end-point was combined end point of cardiac death and hospitalization for heart failure...
February 26, 2017: World Journal of Cardiology
https://www.readbyqxmd.com/read/28271625/clinical-characteristics-of-patients-from-the-worldwide-registry-on-peripartum-cardiomyopathy-ppcm-eurobservational-research-programme-in-conjunction-with-the-heart-failure-association-of-the-european-society-of-cardiology-study-group-on-ppcm
#19
Karen Sliwa, Alexandre Mebazaa, Denise Hilfiker-Kleiner, Mark C Petrie, Aldo P Maggioni, Cecile Laroche, Vera Regitz-Zagrosek, Maria Schaufelberger, Luigi Tavazzi, Peter van der Meer, Jolien W Roos-Hesselink, Petar Seferovic, Karin van Spandonck-Zwarts, Amam Mbakwem, Michael Böhm, Frederic Mouquet, Burkert Pieske, Roger Hall, Piotre Ponikowski, Johann Bauersachs
AIMS: The purpose of this study is to describe disease presentation, co-morbidities, diagnosis and initial therapeutic management of patients with peripartum cardiomyopathy (PPCM) living in countries belonging to the European Society of Cardiology (ESC) vs. non-ESC countries. METHODS AND RESULTS: Out of 500 patients with PPCM entered by 31 March 2016, we report on data of the first 411 patients with completed case record forms (from 43 countries) entered into this ongoing registry...
March 8, 2017: European Journal of Heart Failure
https://www.readbyqxmd.com/read/28262346/effective-suppression-of-atrial-fibrillation-by-ivabradine-novel-target-for-an-established-drug
#20
Gerrit Frommeyer, Magdalena Sterneberg, Dirk G Dechering, Christian Ellermann, Nils Bögeholz, Simon Kochhäuser, Christian Pott, Michael Fehr, Lars Eckardt
BACKGROUND: Ivabradine is an inhibitor of mixed Na(+)-K(+)-currents and routinely administered in chronic heart failure. Clinical studies reported divergent trends regarding proarrhythmic and antiarrhythmic effects in atrial fibrillation (AF). METHODS AND RESULTS: In 12 isolated rabbit hearts AF was induced in 7 of 12 hearts (13 episodes) under baseline conditions by a standardized protocol employing atrial burst pacing. Thereafter, a combination of acetylcholine and isoproterenol was employed to enhance AF occurrence...
February 27, 2017: International Journal of Cardiology
keyword
keyword
6588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"